Retatrutide: the triple GLP-1/GIP/glucagon agonist
Structure, triple agonism and clinical status of the investigational compound LY3437943 — a neutral overview, with no claims.
Drag to rotate · scroll to zoomStylised 3D representation — illustration, not to scale.
Identity card
- Class
- Triple GLP-1 / GIP / glucagon agonist
- Sequence
- 39 acides aminés · peptide lipidé (Aib, N-Me-Leu)
- Discovery
- Developed by Eli Lilly (code LY3437943)
A triple receptor agonist
Retatrutide (development code LY3437943, Eli Lilly) is a synthetic 39-amino-acid peptide, chemically modified and lipidated to extend its half-life.
It acts as an agonist — not an antagonist — of three hormone receptors: GLP-1, GIP and glucagon. This triple agonism is what sets it apart from single or dual agonists.
An investigational, unapproved compound
Retatrutide is studied in clinical trials (the phase 3 TRIUMPH programme) in the context of obesity and type 2 diabetes. To date, it is not approved.
A compound 'under study' is not an 'approved' compound: trial results are neither authorisation nor a usage recommendation.
Research framing
This compound is presented here for strictly educational purposes. It is intended solely for laboratory research (RUO), with no human use.
Strictly educational and scientific content. No effect, benefit or human use is described. Products are intended solely for laboratory research (RUO): they are neither medicines nor food supplements. For any health question, consult a qualified professional.